Your Apo E genotype plays part in likelihood of Alzheimer's and heart disease

We all carry the Apo E gene. It plays a key role in the development of Alzheimer's Disease and heart disease, along with a host of chronic ailments.

And it is greatly affected by diet.

In her seminal book, The Apo E Gene Diet: A Breakthrough in Changing, Cholesterol, Weight, Heart and Alzheimer's Using the Body's Own Genes (Elite, Hardcover, $27.95, November 1, 2007), Pamela McDonald, RNFA, FNP, an integrative healthcare professional for 28 years, has developed specific diets that support an individual's Apo E genotype.

The Apo E Gene Diet accomplishes what one-size-fits-all diets like Atkins and South Beach can never do: it prescribes the optimal combination of proteins, carbohydrates and fates for specific genotypes. The six Apo E genotypes -- Apo E 2/2, 2/3, 3/3, 4/2, 4/3, 4/4 -- responds differently to these big three macronutrients.

  • Apo E type 2/2: high risk for heart disease and vascular dementia
  • Apo E type 2/3: high risk for heart disease and vascular dementia
  • Apo E type 3/3 (the most common genotype): high risk for metabolic disease and 20% chance of Alzheimer's
  • Apo E type 4/2: greater risk for high cholesterol and 50% chance of Alzheimer's
  • Apo E type 4/3: increased risk for high cholesterol and 60% chance of Alzheimer's
  • Apo E type 4/4: 92% chance of Alzheimer's

As Larry Dossey, MD, bestselling author of The Extraordinary Healing Power of Ordinary Things, writes, "This book represents the future of medicine -- an individualized, personalized approach that honors our genetic uniqueness."

McDonald supports her diet with scientific research and decades of advanced specialty training in areas including women's health, family practice, nutrition, exercise sports medicine and heart disease prevention. A leading integrative medicine practitioner with a practice in Danville, CA, McDonald is a faculty member with the Nutrition and Health Conference -- State of the Science and Clinical Application and a graduate of the University of Arizona's Program of Integrative Medicine.

A simple blood test determines your Apo E genotype; for those not interested in knowing their genotype, Pamela McDonald provides dietary information that benefits the gene, plus suggestions for a gene supportive environment including appropriate exercise, physical environments, mental and emotional experiences, and spiritual beliefs.

Comments

  1. Judy Bard Judy Bard United States says:

    I was recently tested for APO E Genotype.  I was rated as a 4/3 Genotype.  This is the higher risk of ALh. disease.  I received some information from my primary care doctor, but I would like to view more.  I understand that diet and exercise play an important part in my life.  I am 70 years old and considered quite healthy for my age.  I have been taking B-12 shots since 1995.  Am on a cholesterol lowering medication, and thyroid med, also.  In 1975 I had a few seizures,and the cause was undetermined, after going through a battery of tests.  I have been on phenytoin since then.  I am really trying to improve my health, by following a non-red meat diet.  Mostly meditteranean - but I would like to get a list of foods to avoid.  

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study: 40% of newly diagnosed heart failure patients also have atrial fibrillation